Live News EQUITY ARTICLE L impact Jun 30, 2026, 05:01 PM UTC

B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price Target

B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Buy and maintains $22 price target.

SquawkNews Newsroom

Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Buy and maintains $22 price target.